

11-24-20

PERFORMANCE GAP/ ACTIVITY NEED: Preliminary results from two placebo-controlled trials for SARS-COV-2 vaccines have been reported in press releases:

- An mRNA SARS-CoV-2 vaccine (BNT162b2, given in two intramuscular doses 21 days apart) had >90 percent vaccine efficacy in preventing symptomatic COVID-19 at or after day 7 following the second dose.
- An mRNA SARS-CoV-2 vaccine (mRNA-1273, given in two intramuscular doses 28 days apart) had 94.5 percent vaccine efficacy in preventing symptomatic COVID-19 at or after two weeks following the second dose [Source: UpToDate]. What are some of the challenges for vaccine development and distribution and implications for eventual herd immunity in COVID-19?

DESIRED OUTCOMES: At the end of the activity, attendees will be able to:

- evaluate preliminary data from two placebo-controlled trials showing COVID-19 vaccine efficacy of 90+ percent.
- discuss how the different vaccine technologies will impact our potential distribution strategies.
- discuss how herd immunity works and two ways to achieve it.
- prepare to assess cultural diversity issues in risk, incidence, prevalence, disease burden, or mortality associated with COVID-19 and/or cultural disparities in access, diagnosis at more advanced stages, or less adherence to treatment regimens.

LEARNERS: all clinicians

DESIRABLE PHYSICIAN ATTRIBUTE: provide patient-centered care, apply evidence-based practice